Cardiovascular Effects of 3 Months of Treatment with GLP-1 Receptor Agonist Exenatide and DPP-4 Inhibitor Linagliptin: The SAFE-GUARD Trial
Journal article published in 2016 by
Milos Mraz,
Eva Chytilova,
Jana Klouckova,
Pavel Trachta,
Jan Skrha,
Jarmila Krizova,
Ondrej Petrak,
Jan Krupicka,
Vladimir Tuka,
Jaroslav Kudlicka,
Zuzana Kratka 
,
Gabriela Dostalova,
Jan Malik ,
Martin Haluzik
,
Gabriela Dostalova,
Jan Malik ,
Martin Haluzik
